Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBESIAL
NCT07779343Recruiting
- Sponsor
- Sağlık Bilimleri Üniversitesi
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in obesity (3 arms), sponsored by Sağlık Bilimleri Üniversitesi. Primary endpoint: Percentage of Participants Achieving ≥5% Weight Loss at 18 months. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07779343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779343.